Who makes Indium-111 Pentreotide?

Indium-111 Pentreotide is developed by Marcelo F. Di Carli, MD, FACC.

What development phase is Indium-111 Pentreotide in?

Indium-111 Pentreotide is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Indium-111 Pentreotide

Marcelo F. Di Carli, MD, FACC · Phase 1 active Small molecule

At a glance

Generic name	Indium-111 Pentreotide
Also known as	OctreoScan
Sponsor	Marcelo F. Di Carli, MD, FACC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Indium-111 Pentreotide CI brief — competitive landscape report
Indium-111 Pentreotide updates RSS · CI watch RSS
Marcelo F. Di Carli, MD, FACC portfolio CI